ReviewJournal of clinical medicine2025
The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Sustainable Synthesis of 4,7-Dihydro-4,7-ethano-2H-isoindoles-Key Building Blocks to Benzoporphyrins.Chemistry (Weinheim an der Bergstrasse, Germany) · 2026Article
- Advancements and emerging trends in photodynamic therapy: innovations in cancer treatment and beyond.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Photodynamic therapy (PDT) has been approved as a therapeutic modality for the management of neovascular age-related macular degeneration (nAMD). PDT can treat macular neovascularization with minimal effects on normal tissue, reducing lesion size and maintaining patients' visual acuity; consequently, it became the choice of intervention for nAMD around the year 2000. However, the visual outcomes of PDT are inferior to those of anti-vascular endothelial growth factor therapy. Thus, PDT is no longer favored, except for the management of some specific phenotypes of nAMD (e.g., polypoidal choroidal vasculopathy and pachychoroid neovasculopathy) that are good candidates for PDT. Despite these circumstances, PDT remains an effective treatment modality for several retinal and choroidal diseases and should be considered for further use. This review summarizes the past and present positions of PDT in the field of ophthalmology and discusses the future perspectives on PDT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.